Ulviprubart (ABC008)

Phase 3Small molecule

AAbcuro, Inc.

Ulviprubart (ABC008) is one of 4 small molecule programs targeting Inclusion Body Myositis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inclusion Body MyositisActive, not recruiting

Inclusion Body MyositisPhase 3

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Inclusion Body Myositis

#DrugCompanyPhaseTrials

Rapamune

PPrism Pharmaceuticals

Jakafi

1 3

Ulviprubart (ABC008)

AAbcuro, Inc.

Phase 3

1 4

Care as Usual

UUniversity of Southern Denmark

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2/3Active, not recruiting

Inclusion Body Myositis

NCT06450886

Clinical

Trials by Indication[1]

Inclusion Body Myositis1 trial

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

Active, not recruiting·AAbcuro, Inc.·Phase 2/3·NCT06450886·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ulviprubart (ABC008). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ulviprubart (ABC008) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ulviprubart (ABC008). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Abcuro, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAbcuro, Inc.

Ulviprubart (ABC008)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Inclusion Body Myositis1 trial

References

Drug Info

Quick Facts

Related News